Agios Pharmaceuticals Inc (NASDAQ: AGIO) on Tuesday, soared 3.04% from the previous trading day, before settling in for the closing price of $35.21. Within the past 52 weeks, AGIO’s price has moved between $23.42 and $62.58.
Here's Your FREE Report on the #1 Small-Cap Uranium Stock of '24.
Small-cap Uranium stocks are booming in 2024! The company we're about to show you is the ONLY small-cap stock in the space that benefits from ALL aspects of the global Uranium industry with none of the risks of running a mine. Smart investors will not be hesitating on this one!
Get the FREE Report with all the details here.
Sponsored
The company achieved an average annual earnings per share of -162.17%. With a float of $55.38 million, this company’s outstanding shares have now reached $57.89 million.
In an organization with 488 employees, it is important to assess its efficiency. In terms of profitability, gross margin is 83.22%, operating margin of -1188.86%, and the pretax margin is 1917.72%.
Agios Pharmaceuticals Inc (AGIO) Insider and Institutional Ownership
Observing investor behavior towards Biotechnology industry stocks is more important than anything else. The insider ownership of Agios Pharmaceuticals Inc is 4.37%, while institutional ownership is 105.23%. The most recent insider transaction that took place on Jul 01 ’25, was worth 139,789. In this transaction Chief Medical Officer of this company sold 4,091 shares at a rate of $34.17, taking the stock ownership to the 61,271 shares. Before that another transaction happened on Jul 01 ’25, when Company’s Officer proposed sale 4,091 for $34.37, making the entire transaction worth $140,608.
Agios Pharmaceuticals Inc (AGIO) Latest Financial update
According to the Wall Street analysts, stocks earnings will be around -162.17% per share during the next fiscal year.
Agios Pharmaceuticals Inc (NASDAQ: AGIO) Trading Performance Indicators
Agios Pharmaceuticals Inc (AGIO) is currently performing well based on its current performance indicators. A quick ratio of 17.93 was reported for the most recent quarter. In addition, a publicly-traded company’s price to sales ratio for the trailing twelve months stands at 56.74.
For the trailing twelve months, Company’s Diluted EPS (Earnings per Share) is 11.29, a number that is poised to hit -1.81 in the next quarter and is forecasted to reach -6.64 in one year’s time.
Technical Analysis of Agios Pharmaceuticals Inc (AGIO)
Let’s dig in a bit further. During the last 5-days, its volume was 0.54 million. That was inferior than the volume of 0.66 million it reported in year-ago period. As of the previous 9 days, the stock’s Stochastic %D was 86.51%.
During the past 100 days, Agios Pharmaceuticals Inc’s (AGIO) raw stochastic average was set at 96.01%, which indicates a significant increase from 87.50% during the past two weeks. Based on volatility metrics of the stock, it showed a historical volatility of 1.36 in the past 14 days, which was lower than the 1.42 volatility it showed in the past 100 days.
At the time of writing, stock’s 50-day Moving Average is $31.91, while its 200-day Moving Average is $37.36. However, in the short run, Agios Pharmaceuticals Inc’s stock first resistance to watch stands at $37.04. Second resistance stands at $37.79. The third major resistance level sits at $38.77. If the price goes on to break the first support level at $35.30, it is likely to go to the next support level at $34.32. The third support level lies at $33.57 if the price breaches the second support level.
Agios Pharmaceuticals Inc (NASDAQ: AGIO) Key Stats
Market capitalization of the company is 2.10 billion based on 57,915K outstanding shares. Right now, sales total 36,500 K and income totals 673,730 K. The company made 8,730 K in profit during its latest quarter, and -89,290 K in sales during its previous quarter.
